Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124793) titled 'A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Condition:
EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
Intervention:
Drug: IBI363+IBI305
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 31, 2025
Target Sample Size: 60
Countries of Recruitment:
China
To know more, visit https://clinicaltrials....